Featured, Health Care

Orforglipron vs. Semaglutide: A New Era in Diabetes Treatment

Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

  • For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3
  • In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight loss
  • Lilly has submitted orforglipron to regulators in over 40 countries, with potential U.S. action for obesity in Q2 2026

INDIANAPOLIS, March 24, 2026 — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants across four treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg. In ACHIEVE-3, orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints, delivering significantly greater improvements in A1C and weight.1,2 The results were published today in The Lancet.

Continue reading Orforglipron vs. Semaglutide: A New Era in Diabetes Treatment →
Technologies

HUAWEI Mate 80 Pro: The Return of a Flagship Powerhouse

UAE, March 24, 2026 – The Mate series once represented the pinnacle of smartphone innovation. Now, the series returns to the global stage after a brief hiatus. Building on the Mate series’ strong tradition of pioneering technology, the Mate 80 Pro sets new standards in imaging authenticity, durability, performance, and intelligence. At a time when innovation among standard slab smartphones appears to have stalled, the Mate 80 Pro emerges as a serious contender for the best flagship smartphone of the year.

Continue reading HUAWEI Mate 80 Pro: The Return of a Flagship Powerhouse →
Technologies

Vault22 Launches AI-Driven Wealth Platform in UAE

The unified platform integrates budgeting, investing, and Shariah-compliant solutions

Dubai, UAE, March 2026: Fintech platform Vault22 has launched in the United Arab Emirates, introducing an AI-powered wealth platform designed to help individuals budget, save, and invest more effectively through a single digital application.

At its core, Vault22 is designed to simplify how people manage money. Instead of juggling multiple banking apps, spreadsheets and investment platforms, users can see their bank accounts, investments, liabilities and financial goals in one intelligent dashboard, helping them better understand their financial position and make clearer long-term decisions.

Continue reading Vault22 Launches AI-Driven Wealth Platform in UAE →
Technologies

Yango Tech Unveils AI Agents to Transform UAE Workforce

Yango Tech launches Industrial AI Agents to accelerate UAE’s digital workforce agenda

Dubai, UAE, 24 March 2026: Yango Tech, B2B technology solutions provider by Yango Group, launches a new business practice focused on developing and deploying autonomous industrial AI agents. These AI agents are designed to execute real operational tasks across customer service, analytics, compliance, and decision-making, serving industries such as fintech, medtech, e-commerce, logistics, smart cities, and the public sector.

Yango Tech offers both ready-to-deploy solutions and a customizable platform for building AI agents tailored to the specific needs of each business. This new business direction addresses the rapidly growing demand across the Middle East for scalable AI systems that deliver measurable business impact, as the region accelerates toward a projected $320 billion AI economy by 2030.

Continue reading Yango Tech Unveils AI Agents to Transform UAE Workforce →
Health Care

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

Dubai, 24 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term. The FDA awarded a Commissioner’s National Priority Voucher for Wegovy® HD, accelerating its review and underscoring its potential to address critical patient needs and national health priorities in the US.

The accelerated approval is based on results from the STEP UP trial programme. In the STEP UP trial, semaglutide 7.2 mg injected once weekly demonstrated 20.7%1 mean weight loss in participants with obesity, and approximately one in three people experienced 25% or greater weight loss. In the STEP UP type 2 diabetes (T2D) trial, in participants with obesity and type 2 diabetes, semaglutide 7.2 mg demonstrated a mean weight loss of 14.1%1. In both trials, the well-known safety and tolerability profile of semaglutide was reaffirmed with semaglutide 7.2 mg, which was comparable to previous trials with semaglutide for weight management.

Continue reading Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss →